[Skip to Navigation]
Sign In
Comment & Response
October 2018

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework

Author Affiliations
  • 1Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Hôtel Dieu, Centre d’Épidémiologie Clinique, Paris, France, INSERM U1153
JAMA Oncol. 2018;4(10):1437-1438. doi:10.1001/jamaoncol.2018.3289

To the Editor In a recent study, Ben-Aharon et al1 showed that only 3 of 10 indications of immune checkpoint inhibitors qualified for tail-of-the-curve bonus points of the American Society of Clinical Oncology Value Framework (ASCO-VF).2 We were puzzled by these counterintuitive findings in light of previous studies using the ASCO-VF and of our experience.3 The authors called for lowering the bar so that more trials could reach thresholds.

Add or change institution
×